Richard Riedel
About
Richard Riedel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Richard Riedel has authored 28 papers receiving a total of 128 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Richard Riedel's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (5 papers) and Cancer Genomics and Diagnostics (5 papers). Richard Riedel is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (5 papers) and Cancer Genomics and Diagnostics (5 papers). Richard Riedel collaborates with scholars based in Germany, United States and Austria. Richard Riedel's co-authors include Erich Stoelben, Corinna Ludwig, Sebastian Michels, Sabine Merkelbach‐Bruse, Nikolaj Frost, Klaus Fenchel, Reinhard Büttner, Frank Griesinger, Frank Beckers and Matthias Scheffler and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.
In The Last Decade
Richard Riedel
21 papers receiving 121 citations
Peers
Richard Riedel
Chinyere E. Okpara United States
Ernesto Korbenfeld Argentina
Kylie Prutisto-Chang United States
Sucheta More India
Patricia Maeda United States
Aiping Zhou China
Patrick O’Donnell United States
Carole A. Harris Australia
Kato Kambartel Germany
Jesús Corral Jaime Spain
Citations per year, relative to Richard Riedel Richard Riedel (= 1×)
peers
Chinyere E. Okpara
Countries citing papers authored by Richard Riedel
Since
Specialization
Citations
This map shows the geographic impact of Richard Riedel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Riedel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Riedel more than expected).
Fields of papers citing papers by Richard Riedel
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Richard Riedel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Riedel. The network helps show where Richard Riedel may publish in the future.
Co-authorship network of co-authors of Richard Riedel
This figure shows the co-authorship network connecting the top 25 collaborators of Richard Riedel. A scholar is included among the top collaborators of Richard Riedel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Riedel. Richard Riedel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Riedel, Richard, Lucia Nogová, Sebastian Michels, et al.. (2025). MET-Driven Resistance to Sotorasib in KRAS G12C–Mutant NSCLC and Response to Combined KRAS and MET Inhibition. JTO Clinical and Research Reports. 7(3). 100925–100925.
2.
Meyer, Mathias, Hideki Ota, Christina Messiou, et al.. (2024). Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy—Impact on clinical outcome. International Journal of Cancer. 155(11). 2047–2057.
3.
Fassunke, Jana, Michael Püsken, Elke Binot, et al.. (2023). Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report. JCO Precision Oncology. 7(7). e2200467–e2200467.
4.
George, Julie, Andreas H. Scheel, Hans Anton Schloesser, et al.. (2022). 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort. Annals of Oncology. 33. S1025–S1025.
5.
Kron, Anna, Sebastian Michels, Lucia Nogová, et al.. (2022). 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Annals of Oncology. 33. S1006–S1006.
6.
Levetzow, Cornelia von, Sebastian Michels, Lucia Nogová, et al.. (2022). 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. Annals of Oncology. 33. S56–S57.
7.
Seeber, Andreas, Andrew Elliott, Jaime F. Modiano, et al.. (2022). Age as a factor in the molecular landscape and the tumor-microenvironmental signature of osteosarcoma.. Journal of Clinical Oncology. 40(16_suppl). 11525–11525.
8.
Malchers, Florian, Axel M. Hillmer, Sabine Merkelbach‐Bruse, et al.. (2022). Screening of FGFR patients for FGFR directed clinical trials in Network Genomic Medicine (NGM): Real-world data.. Journal of Clinical Oncology. 40(16_suppl). e21013–e21013.
9.
Frost, Nikolaj, Diego Kauffmann‐Guerrero, Jan Stratmann, et al.. (2020). 1368P Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program. Annals of Oncology. 31. S874–S874.
10.
Heydt, Carina, Roberto Pappesch, Udo Siebolts, et al.. (2019). Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors. Journal of Molecular Diagnostics. 21(6). 971–984.
11.
Riedel, Richard, Sebastian Michels, Carina Heydt, et al.. (2019). Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma. Lung Cancer. 133. 20–22.
12.
Abdulla, Diana S.Y., Matthias Scheffler, Carsten Kobe, et al.. (2019). Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.. Journal of Clinical Oncology. 37(15_suppl). e20682–e20682.
13.
Michels, Sebastian, Lucia Nogová, Barbara Deschler-Baier, et al.. (2019). EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.. Journal of Clinical Oncology. 37(15_suppl). e20577–e20577.
14.
Abdulla, Diana S.Y., Matthias Scheffler, Maximilian I. Ruge, et al.. (2018). Monitoring Treatment Response to Erlotinib in EGFR-mutated Non–small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET. Clinical Lung Cancer. 20(2). e148–e151.
15.
Nogová, Lucia, Florian Malchers, Axel M. Hillmer, et al.. (2018). P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S490–S490.
16.
Michels, Sebastian, Matthias Scheffler, Dennis Plenker, et al.. (2018). Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. JCO Precision Oncology. 2(2). 1–6.
17.
Riedel, Richard, Anna Kron, Sebastian Michels, et al.. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Annals of Oncology. 28. v474–v474.
18.
Kron, Anna, Richard Riedel, Sebastian Michels, et al.. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Annals of Oncology. 28. v461–v462.
19.
Riedel, Richard, et al.. (2017). The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer. Lung Cancer. 109. 68–73.
20.
Ludwig, Corinna, et al.. (2009). Inhalation with Tobramycin® to improve healing of tracheobronchial reconstruction☆. European Journal of Cardio-Thoracic Surgery. 35(5). 797–800.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Chinyere E. Okpara Breakdown of academic impact, for papers by Ernesto Korbenfeld Breakdown of academic impact, for papers by Kylie Prutisto-Chang Breakdown of academic impact, for papers by Sucheta More Breakdown of academic impact, for papers by Patricia Maeda Breakdown of academic impact, for papers by Aiping Zhou Breakdown of academic impact, for papers by Patrick O’Donnell Breakdown of academic impact, for papers by Carole A. Harris Breakdown of academic impact, for papers by Kato Kambartel Breakdown of academic impact, for papers by Jesús Corral Jaime